PETACH-TIKVA, ISRAEL--(Marketwire - December 15, 2008) - Aposense Ltd., a leading developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced the initiation of a Phase II, Multi-Center Study of its [18F]-ML-10 compound for molecular imaging of apoptosis at Memorial Sloan-Kettering Cancer Center, following approval by its Institutional Review Board (IRB). This study aims to evaluate the safety and efficacy of [18F]-ML-10 in early assessment of response of metastatic brain tumors to high-dose, single-fraction radiotherapy (also known as stereotactic radiosurgery).
